Yu Renzhi, Wang Minghuan, Zhu Xiuli, Sun Zhe, Jiang Aiying, Yao Huixin
Department of Respiratory Medicine, Mudanjiang Medical University Affiliated HongQi Hospital, Mudanjiang, Heilongjiang 157000, P.R. China.
Community Health Service Center, Medical University Affiliated HongQi Hospital, Mudanjiang, Heilongjiang 157000, P.R. China.
Oncol Lett. 2018 Nov;16(5):6573-6581. doi: 10.3892/ol.2018.9428. Epub 2018 Sep 11.
The aim of the present study was to analyze the effects of the combined treatment of lenvatinib and adenoviral delivered p53 gene (rAd-p53) on non-small cell lung cancer (NSCLC) cells and a total of 120 patients with NSCLC. The therapeutic effects of gene therapy of rAd-p53 and target therapy of Lenvatinib were investigated in NSCLC patients. The anti-tumor effects of combined treatment of llenvatinib and rAd-p53 was administered orally once-daily in NSCLC patients. Patients with NSCLC were divided into three groups and received lenvatinib (n=40), rAd-p53 (n=40) or combined treatment of lenvatinib and rAd-p53 (n=40) for a total of 30 days. Results showed that p53 was down-regulated and VEGFR, FGFR and PDGFR-β were up-regulated in NSCLC tissues compared to adjacent normal tissues. Combined treatment of Lenvatinib and rAd-p53 markedly inhibited NSCLC cell growth, migration and invasion, and promoted apoptosis compared to either lenvatinib or rAd-p53 alone. The most common treatment-related adverse events included hypertension, diarrhea, nausea, proteinuria and body weight loss. Outcomes indicated that combined treatment of lenvatinib and rAd-p53 markedly inhibited tumor growth compared to lenvatinib and rAd-p53 alone for NSCLC patients. Combined treatment of lenvatinib and rAd-p53 did not exhibit drug accumulation after 30-day treatment. In conclusion, these outcomes indicate that combined treatment of lenvatinib and rAd-p53 may be an efficient therapeutic schedule for the treatment of NSCLC patients.
本研究的目的是分析乐伐替尼与腺病毒介导的p53基因（rAd-p53）联合治疗对非小细胞肺癌（NSCLC）细胞和总共120例NSCLC患者的影响。在NSCLC患者中研究了rAd-p53基因治疗和乐伐替尼靶向治疗的疗效。乐伐替尼和rAd-p53联合治疗的抗肿瘤作用在NSCLC患者中每日口服一次。NSCLC患者分为三组，分别接受乐伐替尼（n = 40）、rAd-p53（n = 40）或乐伐替尼与rAd-p53联合治疗（n = 40），共30天。结果显示，与相邻正常组织相比，NSCLC组织中p53表达下调，VEGFR、FGFR和PDGFR-β表达上调。与单独使用乐伐替尼或rAd-p53相比，乐伐替尼和rAd-p53联合治疗显著抑制NSCLC细胞生长、迁移和侵袭，并促进细胞凋亡。最常见的治疗相关不良事件包括高血压、腹泻、恶心、蛋白尿和体重减轻。结果表明，与单独使用乐伐替尼和rAd-p53相比，乐伐替尼和rAd-p53联合治疗对NSCLC患者的肿瘤生长有显著抑制作用。乐伐替尼和rAd-p53联合治疗30天后未出现药物蓄积。总之，这些结果表明，乐伐替尼和rAd-p53联合治疗可能是治疗NSCLC患者的一种有效治疗方案。
